Pan-Asian hospital group IHH Healthcare has announced its CEO will change at the end of 2019, a refinancing of up to $250m of non-Lira debt and its Fortis deal boosted Q1 2019 results, while its Turkish subsidiary Acibadem is reportedly eyeing an investment in London.
The sale of pan-Asian hospital group Columbia Asia is "on track and going well" despite the surprise announced departure of its CEO Dr Kelvin Loh, who will join larger competitor IHH Healthcare at the end of the year.
Two trade buyers and sovereign wealth funds have reportedly joined private equity firms in the process to acquire pan-Asian hospital group Columbia Asia. We hear which one of the trade buyers is really in the running and which isn't.
American investor Columbia Pacific Management has appointed Morgan Stanley to advise on its sale of Columbia Asia, the portfolio of hospitals in Vietnam, Malaysia, India and Indonesia, with a reported price tag of up to $2bn which we think is ambitious.
Pan-Asian hospital group IHH Healthcare saw 3% revenue growth, 9% EBITDA growth but a 35% plummet in post-tax profits in 2018. The results confirm its struggles in Turkey.
As HBI predicted in November, some of the world's largest private equity firms are lining up bids for Columbia Pacific Management's pan-Asian hospital group Columbia Asia.
A month ago we wrote that pan-Asian hospital group IHH Healthcare might be looking to exit its Turkish subsidiary, Acibadem. Over the past week, it revealed a loss in Q3 because of the Lira's fall and also announced a new single-largest shareholder. One source suggests it might be looking to sell before March's local elections in Turkey.
American investor Columbia Pacific Management is reported to be considering a sale of its India, Vietnam, Malaysia and Indonesia hospital business for a touted price tag of $2bn. That would make it the largest deal in Asian hospitals since IHH bought Parkway Pantai in 2010. We discuss potential buyers and what is driving this.
Recent developments point to pan-Asian hospital group IHH scaling down Acibadem, its Turkey-based subsidiary. What does this mean for its interest in Europe? We talk to well-placed sources about what a falling lira, shareholder restructuring, asset sales in Bulgaria and Macedonia, and IHH’s acquisition of Indian chain Fortis might mean.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
